Zimmer Biomet (ZBH) PT Lowered to $128 at Truist Securities

Zimmer Biomet (ZBH) PT Lowered to $130 at Stifel

Stifel analyst Rick Wise lowered the price target on Zimmer Biomet (NYSE: ZBH) to $130.00 (from $178.00) while maintaining a Buy rating.

The analyst commented, "Against continued COVID-related procedure delays, ZBH delivered perhaps better-than-anticipated 4Q21 sales/EPS results, roughly in-line with Stifel/Consensus estimates. Despite this... More

Zimmer Biomet (ZBH) PT Lowered to $129 at Citi

Citi analyst Joanna Wuensch lowered the price target on Zimmer Biomet (NYSE: ZBH) to $129.00 (from $150.00) while maintaining a Buy rating.... More

Zimmer Biomet (ZBH) PT Lowered to $145 at JMP Securities

JMP Securities analyst David Turkaly lowered the price target on Zimmer Biomet (NYSE: ZBH) to $145.00 (from $175.00) while maintaining a Market Outperform rating.... More

Canaccord Genuity Downgrades Zimmer Biomet (ZBH) to Hold

Canaccord Genuity analyst Kyle Rose downgraded Zimmer Biomet (NYSE: ZBH) from Buy to Hold with a price target of $125.00 (from $165.00).
Analyst comments: "From a longer-term perspective, we are unlikely to change our view that the structural, operational, and cultural turnaround has already taken... More

Zimmer Biomet (ZBH) PT Lowered to $143 at Needham & Company

Needham & Company analyst Mike Matson lowered the price target on Zimmer Biomet (NYSE: ZBH) to $143.00 (from $155.00) while maintaining a Buy rating.

The analyst commented, "ZBH's 4Q21 revenue and EPS missed consensus due to a sales reserve taken to account for the China trauma tender announced 1/24/22.... More

Zimmer Biomet (ZBH) Shares Fall on Results, Outlook Miss; Analysts Disappointed

Shares of Zimmer Biomet (NYSE: ZBH) are down over 7% in todays trading session after the medical device company reported disappointing quarterly results and 2022 expectations.

Zimmer Biomet reported Q4 EPS of $1.95, $0.03 worse than the analyst estimate of $1.98. Revenue for the quarter came in at $2.04 billion versus the consensus estimate of $2.07 billion.

For... More

Zimmer Biomet Holdings (ZBH) Misses Q4 EPS by 3c, Offers Guidance

Zimmer Biomet Holdings (NYSE: ZBH) reported Q4 EPS of $1.95, $0.03 worse than the analyst estimate of $1.98. Revenue for the quarter came in at $2.04 billion versus the consensus estimate of $2.07 billion.

GUIDANCE:

Zimmer Biomet Holdings sees FY2022 EPS of $6.40-$6.80 vs 7.93 consensus.